Nicholas K. Foreman

Nicholas K. Foreman

Auto-generated profile, based on publicly available information

Nicholas K. Foreman

Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children’s Hospital Colorado , Aurora, Colorado

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Cancer Cell
Verified
Journal Article
Closed access
DSDominik Sturm
Dominik Sturm
HWHendrik Witt
Hendrik Witt
VHVolker Hovestadt
Volker Hovestadt
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
DJDavid T.W. Jones
David T.W. Jones
Stefan PfisterStefan Pfister
Stefan Pfister

1 May 2015 in Cancer Cell
Verified
Journal Article
Closed access
Kristian W. PajtlerKristian W. Pajtler
Kristian W. Pajtler
HWHendrik Witt
Hendrik Witt
MSMartin Sill
Martin Sill
DJDavid T.W. Jones
David T.W. Jones
VHVolker Hovestadt
Volker Hovestadt
Stefan PfisterStefan Pfister
Stefan Pfister

6 April 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PBPawel Buczkowicz
Pawel Buczkowicz
CHChristine Hoeman
Christine Hoeman
PRPatricia Rakopoulos
Patricia Rakopoulos
SPSanja Pajovic
Sanja Pajovic
LLLouis Letourneau
Louis Letourneau
CHCynthia Hawkins
Cynthia Hawkins
Cynthia Hawkins, Oren Becher and colleagues report the identification of recurrent mutations in ACVR1 in 20% of diffuse intrinsic pontine gliomas. Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.

1 September 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAlvaro Lassaletta
Alvaro Lassaletta
MZMichal Zapotocky
Michal Zapotocky
MMMatthew Mistry
Matthew Mistry
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy
MHMarion Honnorat
Marion Honnorat
UTUri Tabori
Uri Tabori
Purpose: BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods: A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG (n = 99) were compared with a large international independent cohort of patients with BRAF V600E mutated-PLGG (n = 180). Results: BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P < .001). Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG. A similar independent role for CDKN2A and resection on outcome were observed in the independent cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. Conclusion: BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy.

17 November 2016 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
Kristian W. PajtlerKristian W. Pajtler
Kristian W. Pajtler
SMStephen C. Mack
Stephen C. Mack
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy
CSChristian A. Smith
Christian A. Smith
HWHendrik Witt
Hendrik Witt
MTMichael D. Taylor
Michael D. Taylor
Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

1 November 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AGAndrea M. Griesinger
Andrea M. Griesinger
DBDiane K. Birks
Diane K. Birks
ADAndrew M. Donson
Andrew M. Donson
VAVladimir Amani
Vladimir Amani
LHLindsey M. Hoffman
Lindsey M. Hoffman
NFNicholas K. Foreman
Nicholas K. Foreman
Despite increasing evidence that antitumor immune control exists in the pediatric brain, these findings have yet to be exploited successfully in the clinic. A barrier to development of immunotherapeutic strategies in pediatric brain tumors is that the immunophenotype of these tumors’ microenvironment has not been defined. To address this, the current study used multicolor FACS of disaggregated tumor to systematically characterize the frequency and phenotype of infiltrating immune cells in the most common pediatric brain tumor types. The initial study cohort consisted of 7 pilocytic astrocytoma (PA), 19 ependymoma (EPN), 5 glioblastoma (GBM), 6 medulloblastoma (MED), and 5 nontumor brain (NT) control samples obtained from epilepsy surgery. Immune cell types analyzed included both myeloid and T cell lineages and respective markers of activated or suppressed functional phenotypes. Immune parameters that distinguished each of the tumor types were identified. PA and EPN demonstrated significantly higher infiltrating myeloid and lymphoid cells compared with GBM, MED, or NT. Additionally, PA and EPN conveyed a comparatively activated/classically activated myeloid cell–skewed functional phenotype denoted in particular by HLA-DR and CD64 expression. In contrast, GBM and MED contained progressively fewer infiltrating leukocytes and more muted functional phenotypes similar to that of NT. These findings were recapitulated using whole tumor expression of corresponding immune marker genes in a large gene expression microarray cohort of pediatric brain tumors. The results of this cross-tumor comparative analysis demonstrate that different pediatric brain tumor types exhibit distinct immunophenotypes, implying that specific immunotherapeutic approaches may be most effective for each tumor type.